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We recently showed that carboxymethyl benzylamide dextran
derivative (in particular CMDB7) inhibits the breast cancer cell
proliferation in vitro and in nude mice (Bagheri-Yarmand et al,
1992, 1997, 1998a, b, 1999). This effect in vitro is associated with
a decrease in the S-phase cell population and with an accumulation
of cells in G1 phase of cell cycle (Bagheri-Yarmand et al, 1992).
CMDB7 disrupts the mitogenic effect of growth factors by
preventing their binding to specific receptors as reported for
Fibroblast Growth Factor-2 and -4 (FGF2, FGF4, Bagheri-
Yarmand et al, 1998a), Platelet-Derived Growth Factor-BB and
Transforming Growth Factor-β 1 (PDGF-BB, TGFΒ Bagheri-
Yarmand et al, 1998b). In vivo, CMDB7 treatment reduces the
growth of MCF-7ras (Bagheri-Yarmand et al, 1998b) and FGF4-
transfected HBL100 xenografts and decreases the tumour angio-
genesis (Bagheri-Yarmand et al, 1998a). 
Sodium phenylacetate (NaPa), a physiological metabolite of
phenylalanine, is normally found in human plasma at micromolar
concentrations. At higher concentrations, NaPa was reported to
induce the cytostasis and the reversion of malignant phenotype of
different cancer cells in vitro (Samid et al, 1993, 1994, 1997, 2000;
Adam et al, 1995). Furthermore, NaPa was described to modulate
the synthesis and/or the release of some growth factors
(Ferrandina et al, 1997; Thibout et al, 1998) and to increase, in
synergistic manner, the effect of some molecules affecting the
growth factor pathways (Samid et al, 1993; Prasanna et al, 1996).
For example, NaPa potentiated the antitumour activity of tamox-
ifene by increasing apoptosis induction in breast cancer xenografts
in nude mice. Finally, NaPa had been used in phase I and II clinical
trials on patients with malignant tumours (Thibault et al, 1994;
Chang et al, 1999). 
In this study, we investigated in vitro and in vivo the efficacy of
combined treatment with NaPa and an industrial dextran deriva-
tive LS4 (Sterilyo Laboratories) whose composition is similar to
CMDB7 one, on breast cancer cell growth. We have used the
MCF-7ras cell line obtained by transfection of MCF-7 cells,
isolated from pleural metastasis of breast adenocarcinoma, with v-
Ha-ras oncogene. The MCF-7ras cells secrete high quantities of
TGFα , TGFβ , epithelial growth factor (EGF) and insulin growth
factor (IGF) (Albini et al, 1986). This cell line represents an
oestrogen-independent cellular model corresponding to some
malignant breast tumours (Spandidos and Agnantis, 1984) and
it no requires the oestrogen supplementation to induce a high
incidence of tumours in nude mice (Sommers et al, 1990). The
analysis of CMDBLS4-NaPa combination effect was performed by
the isobole method. Then, we explored the mechanism of action of
CMDBLS4-NaPa combination. 
MATERIALS AND METHODS 
Compound preparation 
NaPa was provided by Seratec (Paris, France). Industrial water-
soluble dextran derivative CMDB named CMDBLS4, was
synthetized by Sterilyo Laboratories (Levallois-Perret, France)
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with some modifications of the procedure described by Mauzac
and Jozefonvicz (1984) and by Chaubet et al (1995). In brief,
CMDBLS4 was prepared by simultaneous carboxymethylation and
benzylamidation of dextran T40 in one step. After purification by
ultrafiltration and lyophilization, the chemical composition (or
degree of substitution, ds) of CMDBLS4 was determined by acidi-
metric titration and elementary analysis of nitrogen. The dextran,
carboxymethyl (CM) and benzylamide (B) was 0, 0.67 and 0.33,
respectively. The average molecular weight, calculated consid-
ering CMDB subunits was PMT40 + dsCM × PMCM + dsB × PMB =
264.1 g mol–1. 
Cell culture 
The human breast cancer MCF-7ras cells, derived from the pleural
effusion MCF-7 cells transfected with v-Ha-ras, were kindly
provided by Dr C Sommers (Georgetown University, Washington,
DC, USA). BALB/c3T3 fibroblasts were purchased from
American Tissue Culture Collection (Rockeville, MA, USA). All
cells were routinely grown in DMEM supplemented with L-gluta-
mine 2 mM, penicillin 50 IU ml–1, streptomycin 50 µ gm l –1, and
fetal calf serum 10% (FCS) (Life Technologies, Inc, Gaithersburg,
MD, USA) at 37˚C in a 5% CO2 humidified atmosphere. 
Growth inhibition experiments 
MCF-7ras cell growth was assessed using the MTT-microculture
tetrazolium assay (Mosmann, 1983). As previously described,
CMDB7 antiproliferative effect is FCS concentration-dependent
with an optimum observed in the presence of 1 to 2% of FCS
(Bagheri-Yarmand et al, 1992). Briefly, the cells (4 × 103) were
incubated in 2% FCS/DMEM for 24 h and then treated with NaPa
or/and CMDBLS4 at different concentrations for 72 h. Then, the
cells were washed with PBS and incubated with 0.1 ml of MTT
2 mg ml–1. Complementary assay of cell cytotoxicity was
performed by trypan blue exclusion test. 
For analysis of DNA synthesis, the bromodeoxyuridine (BrdU)
(Boehringer Kit, Mannheim, Germany) labelling was used. After
incubation of MCF-7ras cells with NaPa at concentrations 1–
40 mM, the BrdU 10 µ M was added for 6 h and its uptake was
measured by monoclonal antibody from mouse–mouse hybrid
cells conjugated with peroxidase (1/100). After 3 washes with
PBS, the substrate reaction with tetramethyl-benzidine was
stopped with 25 µ l of H2SO4, then the absorbance was determined
at 405 nm wavelength using an microplate reader (Biorad,
Marnes-La-Coquette, France). 
The drug interaction between NaPa and CMDBLS4 was evalu-
ated by comparison of the dose–response curves of MTT assay for
single agents and combined treatment. The characteristics of the
combined treatment were then analysed by the isobole method
(Berenbaum, 1981) analysing the equation Ac/Ae + Bc/Be = D,
where Ac and Bc correspond to concentrations of drugs A and B
used in the combined treatment, and Ae and Be are the concentra-
tions of drugs able to produce the same magnitude of effect if used
individually. If D (combination index) < 1, the effect of combina-
tion is synergistic, when D = 1 its effect is additive and in the case
of D > 1 the combined action is antagonistic. Each experiment was
performed in triplicate and the statistical significance (P) of the
difference between D obtained and D = 1 was calculated by the
Student’s t-test. 
Preparation of conditioned medium (CM) 
MCF-7ras cells (1 × 106) were treated with or without NaPa 20
mM for 48 h in DMEM supplemented with FCS 2% and washed
twice with PBS. To obtain conditioned medium (CM) containing
only the growth factors produced by MCF-7ras, the cells were
incubated with serum-free DMEM for 24 h at 37˚C. This medium
(CM) was then harvested and used directly. 
CM experiments 
BALB/c3T3 fibroblasts (5 × 104) were grown until preconfluence
in DMEM supplemented with FCS 10%, washed twice with PBS
and growth-arrested by serum starvation for 24 h. Then, 0.75 ml of
the CM from MCF-7ras cells, treated or not with NaPa, was added
to 0.25 ml of DMEM containing or not the CMDBLS4 or NaPa.
After 48 h, the proliferative effects of the CM was measured by
counting the fibroblasts using a Coulter counter (Coultronics,
Margency, France). 
Cell cycle analysis 
MCF-7ras cells (5 × 104 ml–1) were plated in DMEM supple-
mented with FCS 2%. After 24 h of culture, NaPa was added for
72 h. Then, the cells were treated with BrdU (Pharmingen, San
Diego, CA, USA) for 4 h. The incorporated BrdU was revealed
using an anti-BrdU conjugated with fluorescein isothiocyanate
(Boerhinger Mannheim, Germany). Then, the cells were stained
with propidium iodide (PI) (Boerhinger) for 10 min and were
analysed using a flow cytometer (Coulter Epics Laser, CA, USA). 
Evaluation of cell death 
Trypan blue and propidium iodide (PI) enter into the cells during
the ultimate stage of apoptosis or predominantly the first stage of
necrosis when damage of the cell membrane has occurred. After
the different treatment, the cells were harvested and the cell
viability was determined by trypan blue exclusion. Other aliquot
of the same sample cells were centrifuged and washed with
annexin buffer (Boehringer). To reveal a phosphatidylserine
translocation specific to apoptosis stage, the cells were treated
with a FITC-labelled annexin V (Boerhinger) followed by PI
(Boerhinger) and finally the cells were analysed using a flow
cytometer. 
Xenografts in nude mice 
MCF-7ras cells (5 × 106) were inoculated s.c. near the right
mammary fad pad of 3-week-old athymic nude mice (nu/nu)
(Harlan laboratory, Gannat, France). The animals (n = 40) were
kept in a temperature-controlled room on a 12h:12h light–dark
schedule with food and water ad libitum. This protocol resulted in
the development of single s.c. palpable tumours 4 weeks after cell
inoculation in 90% of the mice. Then, the animals were arbitrarily
placed in control (n = 10) and treated groups (n = 10). NaPa (40
mg kg–1), CMDBLS4 (150 mg kg–1) or CMDBLS4/NaPa combination
(150/40 mg kg–1, respectively) were injected s.c. in 0.1 ml of NaCl
0.9% twice a week for 7 weeks. The control group received s.c.
0.1 ml of NaCl 0.9%. A tumour volume was calculated as previ-
ously described (Bagheri-Yarmand et al, 1998a). 
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Statistical analysis 
Multiple statistical comparisons were performed using ANOVA in
a multivariable linear model. Some statistical comparisons were
conducted using the Mann–Whitney t-test. P < 0.05 was consid-
ered statistically significant. 
RESULTS 
Inhibition of MCF-7ras cell growth by NaPa 
After 72 h exposure, NaPa induced a dose-dependent inhibition
(IC50 = 20 mM) of MCF-7ras cell growth (Figure 1A). This decline
was associated with a similar inhibition of DNA synthesis (Figure
1A) as well as with a decrease in MCF-7ras cell number in S-phase
and a major recruitment of cells in the G0/G1 phase (Figure 1B). 
NaPa induced the cell death but only at high concentration
(40 mM) (Figure 2A). At concentrations ranged from 5 to 30 mM
NaPa did not induce apoptotic, necrotic or toxic effects as showed
by the negative results of trypan blue exclusion test and annexin V
labelling. In the presence of NaPa 40 mM, we observed 40% of
cells double labelled with annexin V/PI. Moreover, this result was
confirmed using trypan blue exclusion test. The apoptotic effect of
NaPa 40 mM on MCF-7ras cells was time-dependent (Figures 2B
and 3). No apoptotic or necrotic effects were observed after 24 h of
treatment (data not shown). After 48 h of treatment, 2 separate
annexin V positive cell populations were observed. The first one
represented 10% of total cells and contained annexin V single
stained cells being in an early apoptotic phase. The other one
included 18% of annexin V/PI double stained cells or trypan blue-
stained cells progressing in a later apoptotis or in the early stage of
necrosis. After 72 h of treatment, only annexin V/PI double-
stained cell population (40%) was found. 
Improvement of MCF-7 ras cell growth inhibition by
CMDBLS4-NaPa combination 
As shown in Figure 4, the antiproliferative effect of CMDBLS4 on
MCF-7ras cells was potentiated in the presence of NaPa 5 mM.
Indeed, CMDBLS4 18 mM alone was not able to inhibit the MCF-
7ras cell growth by more than 38% (IC50 not reached), whereas in
Figure 1 Effect of NaPa on MCF-7ras proliferation (A) and cell cycle
distribution (B). (A) Cells treated with NaPa for 72 h were assessed using
MTT-assay as described in ‘Materials and Methods’. Points represent the
mean (± SD) of 3 independent experiments. (B) Distribution of cells treated
with or without NaPa 5–40 mM in different phases of cell cycle. Each column
represents a mean (± SD) of 3 independent experiments 
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Figure 2 Apoptosis of MCF-7ras induced by NaPa. (A) Apoptosis of MCF-
7ras cells treated with NaPa at various concentrations for 72 h. (B) Apoptosis
of MCF-7ras cells treated with NaPa 40 mM for various time. Each point
represents the mean (± SD) of 3 independent experiments 
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the presence of NaPa 5 mM, CMDBLS4 was more potent and
reduced the cell growth with an IC50 of 12 mM. 
In order to better characterize the inhibition of MCF-7ras cell
growth by CMDBLS4-NaPa combination, we evaluated this
inhibitory effect for various CMDBLS4 and NaPa concentrations
and for their different ratios (CMDBLS4/NaPa) in a range from 0.01
to 8 (Table 1). The inhibition of MCF-7ras cell growth induced by
CMDBLS4–NaPa combination was compared to their single respec-
tive effect. Only for CMDBLS4/NaPa ratios > 1 the inhibitory effect
was potentiated. 
For CMDBLS4/NaPa ratio = 5, an additive inhibition (40–50%)
was observed after 48 h and 72 h when higher drug concentrations
were used (Table 2). A synergistic inhibitory effect was detected
for lower concentrations of CMDBLS4 and NaPa. In all cases of
combined treatment, an increase in MCF-7ras cell growth inhibi-
tion was time-dependent. When used in combination, NaPa and
CMDBLS4 are efficient at much lower concentrations than when
applied separately to induce the same inhibitory effect. The best
combination seems to be 3.7 mM CMDBLS4/0.75 mM NaPa. The
different combined treatments were not cytotoxic as determined
by a trypan blue exclusion test (data not shown). 
Effect of NaPa and CMDBLS4 on MCF-7 ras CM
mitogenic activity on fibroblast proliferation 
Previous reports indicated that MCF-7ras cells secreted the growth
factors mitogenic for BALBc/3T3 fibroblasts (Bagheri-Yarmand
et al, 1998a). We investigated whether CMDBLS4 or NaPa could
influence the mitogenic activity of MCF-7ras cell conditionned
medium (CM) (Figure 5). CM stimulated BALBc/3T3 fibroblast
proliferation 2-fold after 48 h of treatment. The addition of
CMDBLS4 18.5 mM abolished the MCF-7ras CM stimulation of
Table 1 Growth of MCF-7ras cells treated with different CMDBLS4/NaPa combined ratio 
CMDBLS4/NaPa ratio 0.01 0.1 1 2 5 8 
Concentrations C N C N C N C N C N C N 
(mM) 0.05 5 0.5 5 5 5 10 5 18.5 3.7 18 2.25 
CMDBLS4 87.5 ± 0.8 82 ± 2 73 ± 1.7 69 ± 1 65 ± 2 65 ± 2 
NaPa 74 ± 1.7 74 ± 1.7 74 ± 1.7 74 ± 1.7 78 ± 2 78 ± 0.8 
CMDBLS4+NaPa 75 ± 2.8 70 ± 0.5 57 ± 1.8* 51 ± 0.8* 44 ± 2.2* 44 ± 2*
MCF-7ras cells were treated with various ratios of CMDBLS4/NaPa (0.01, 0.1, 1, 2, 5, 8). Cell growth was determined by MTT assay (see ‘Materials
and Methods’). Each value represents the mean of 3 independent experiments. C = Concentration of CMDBLS4 (mM); N = Concentration of NaPa
(mM); *P < 0.05 versus CMDBLS4 or NaPa alone. 
Table 2 Effects of NaPa and CMDBLS4 combination with a ratio = 5 on MCF-7ras cell proliferation 
aCMDBLS4 NaPa % I CMDBLS4 NaPa D 
(Ac; mM) (Bc; mM) (Ae; mM) (Be; mM) 
48 h 
3.7 0.75 33 18.5 17 0.44b
7.4 1.5 45.8 >18.5 30 0.45b
14.8 3 48.1 >18.5 32.1 0.89 
18.5 4 50 >18.5 34 1.12 
72 h 
3.7 0.75 51.4 >18.5 20.6 0.23b
7.4 1.5 54.8 >18.5 23 0.46b
14.8 3 53.3 >18.5 24 0.93 
18.5 4 60.2 >18.5 29 1.13 
a Ac and Bc, concentrations of agents A and B used in the combination treatment; Ae and Be,
concentrations of agents A and B able to produce the same magnitude of effect if used individually.
D combination index (see Materials and Methods). b P < 0.05. % of inhibition determined by MTT assay:
[1–(absorbance of cells in medium containing agents/absorbance of cells in control culture medium)]
× 100. 
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Figure 3 Flow cytometric analysis of annexin V/PI labelled MCF-7ras cells
treated or not with NaPa. MCF-7 ras cells were treated with NaPa 40 mM for
48, 54 and 72 h. Cells were washed with annexin buffer and directly analysed
after addition of annexin V-FITC and PI. FSC (forward scatter)/SSC (side
scatter) pattern are shown in column 1 for control and 3 for NaPa treatment
and annexin V/PI staining profile are shown in column 2 (control) and 4
(NaPa) 
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fibroblasts growth. In contrast, NaPa 20 mM addition did not
affect this CM. However, the pre-treatment of MCF-7ras cells with
NaPa 20 mM for 48 h made a CM less effective on fibroblast
proliferation. 
Antitumour activity of CMDBLS4-NaPa combination on
MCF-7ras cell xenografted into nude mice 
We focused our attention on the in vivo effect of CMDBLS4-NaPa
combination in a ratio of CMDBLS4/NaPa > 1 (Figure 6). NaPa (40
mg kg–1 twice a week) inhibited by 60% (P < 0.05) the growth of
MCF-7ras tumours after 7 weeks of treatment. No apparent
toxicity was reported during mice treatment as their weight
remained stable between day 0: 28.4 g ± 1 and day 7: 30 ± 1.
CMDBLS4 (150 mg kg–1 twice a week) inhibited the tumour growth
by 40% (P < 0.05) after 7 weeks of treatment without toxicity.
When NaPa and CMDBLS4 were administred at the same dose but
in combination, the tumour growth was inhibited by 83% (P ≤
0.001) after 7 weeks and no mice toxicity (mice weight at day 0:
28.9 g ± 0.6, day 7: 33.0 ± 0.01) was noticed. 
DISCUSSION 
Our study demonstrates, for the first time to our knowledge, that
NaPa enhances dextran derivative, CMDBLS4, antiproliferative
effect on breast cancer MCF-7ras cells in vitro and in vivo. Indeed,
NaPa or CMDBLS4, delivered alone for 7 weeks, inhibited MCF-
7ras tumour growth by 60% and 40%, respectively, while the
CMDBLS4-NaPa combination decreased MCF-7ras tumour growth
by 83% without any toxicity. The effectiveness of the NaPa and
CMDBLS4 combination could be explained by their distinct mecha-
nisms of action. MCF-7ras breast cancer cells secrete an important
amount of mitogenic growth factors such as TGFβ and PDGF
(Bronzert et al, 1987; Dickson et al, 1987; Knabbe et al, 1987).
The mitogenic effects of these growth factors could be reduced by
inhibition of their synthesis or/and their action on target cells.
In our study, we showed that a treatment of cells with NaPa
decreased the mitogenic activity of MCF-7ras conditioned
medium on BALBc/3T3. This could be explained by a modulation
of the synthesis and the release of growth factors like TGFβ in
MCF-7ras breast cancer cells as reported previously by our labora-
tory (Thibout et al, 1998). Concerning CMDBLS4, we have demon-
strated here that when added to CM it inhibited CM mitogenic
effect on BALBc/3T3 fibroblasts. This finding argues for
CMDBLS4 interactions with growth factors contained in CM.
Indeed, previous studies showed that dextran derivative interacted
with heparin-binding growth factors like TGFβ , PDGFBB or
FGF-2 and inhibited their mitogenic effect (Bagheri-Yarmand
et al, 1998a, b). All our and others’ observations suggest that NaPa
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opment. NaPa alters the mitogenic growth factor production
and rendered the tumour cells quiescent in the G1 phase while
CMDBLS4 interacts with MCF-7ras growth factors and inhibits
their mitogenic activities. 
The additive and synergistic effect in vitro and in vivo was
observed when the concentrations of CMDBLS4 were 1 to 8-fold
higher than NaPa concentration. If the CMDBLS4/NaPa ratio in
vitro is lower than 0.1, the concentrations of CMDBLS4 are prob-
ably too low to potentiate the NaPa inhibitory effect although they
are efficient when CMDBLS4 is used alone. When the ratio of
CMDBLS4 and NaPa concentrations is higher than 5, the inhibitory
effect was unchanged suggesting that maximal efficiency of treat-
ment is achieved at ratio 5. Within this same ratio, the combined
antiproliferative effect was synergistic when NaPa and CMDBLS4
concentrations were low and it became additive in the case of
higher concentrations. This complexity of interaction between 2
drugs may be due to the fact that at different concentrations the
drugs could induce various effects. For example, we showed that
NaPa at concentration 5 mM, begun to induce G1–S transition
arrest, whereas at higher concentration (40 mM), it generated the
apoptosis after 48 h of treatment of 10% of cell as revealed by a
single annexin V labelling and after 72 h, the destruction of cell
membrane integrity probably due to necrosis or/and later apoptosis
as showed by annexin V/PI labelling. The difficulty to distinguish
the apoptotic cells from the necrotic ones may be, in part,
explained by the fact that some drugs at high doses can induce
new morphological features characteristic of both apoptosis and
necrosis chimerically termed aponecrosis as proposed by Formigli
et al (2000). MCF-7ras cell apoptosis induced by NaPa was previ-
ously described and associated with a reduction of the antiapop-
totic Bc12 gene expression (Adam et al, 1995). 
It is noteworthy that NaPa at high concentrations can induce
pathological effects (Thibault et al, 1994; Chang et al, 1999) that
may involve an induction of cell death as we observed in vitro.
The use of combined treatments, reported in this paper, should
reduce the dose of NaPa without decreasing a therapeutic efficacy
and consequently should limit side effects. Indeed, we observed
here an important MCF-7ras xenograft growth cytostatic inhibi-
tion (83%) using much lower concentrations of NaPa which are
not toxic. Moreover, NaPa does not induce a multi-drug resistance
(Adam et al, 1995). 
In conclusion, our results clearly indicate the complementary
action of NaPa and CMDBLS4 on the autocrine or/and paracrine
loops of growth factors to induce, at low doses, a tumour cell cyto-
static effect. An important perspective of this study is based on the
improvement of the antiproliferative properties of dextran deriva-
tives depending on active subunit substitutions (Bagheri-Yarmand
et al, 1992). Currently, we are investigating the antiproliferative
effect of a carboxymethybenzylamide dextran derivative substi-
tuted with active phenylacetate subunits. 
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